Want to stay updated on the latest mining news?

Stay Informed – Subscribe to latest updates. We promise to send only relevant and valuable emails, just insights you care about!

Zacks Small Cap Research – DYAI: First Product Sales Are Modest


By John Vandermosten, CFA

NASDAQ: DYAI

READ THE FULL DYAI RESEARCH REPORT

Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) announced 3Q:26 results on November 12th, 2026, and hosted a conference call that day. The company recorded its first direct commercial product sales, primarily recombinant transferrin and DNase I, a milestone marking the shift from a research-driven company to a commercial one. The sales were not material, however, and were reported within research and development (R&D) revenue rather than separately. Total revenue fell year over year, largely because of lower Gates Foundation and CEPI grant activity. After quarter end, Dyadic’s partner Inzymes made its first commercial sale of camel chymosin, a second Dapibus-produced cheese-making enzyme. That qualifies Dyadic for a $225,000 milestone payment, which it expects to recognize as revenue in 4Q:26.

Dyadic also updated investors on its partnerships. On November 10th, it announced a collaboration with BRIG BIO and Strive Nutrition to develop, scale and potentially commercialize Dapibus-produced bovine alpha-lactalbumin. The 10-Q also disclosed a research license and development agreement with Nutropy SAS, under which Nutropy will use the Dapibus platform to develop casein proteins. Nutropy paid a $50,000 research license fee for the first contract year and may pay milestones and royalties later.

Management attributed modest product sales to customer qualification activities, which slow conversion of sampling requests into repeat orders. Limited capital has also kept Dyadic from building meaningful inventory, so it is producing to demand. With $6.0 million of cash and investments at September 30 and going-concern doubt disclosed in the 10-Q, the company is putting more weight on larger strategic partnerships, licensing and supply arrangements with partners that have the financial, manufacturing and commercial strength to scale its products.

3Q:26 Operational & Financial Results

Dyadic shared third quarter operational and financial results in a press release and Form 10-Q filing with the SEC. Further detail was provided in a conference call held with investors. Below are financial results for the three months ending September 30th, 2026, compared to the same prior year period:

  • Revenues were $449,000, falling 61% relative to prior year levels. Grant revenue contracted by $538,000, reflecting reduced activities under the Gates Foundation and CEPI grants along with a $188,000 fall in R&D revenue from the completion of several collaboration projects. An offset was license fees of $10,000 versus $0;
  • Cost of revenue totaled $375,000, falling 63% from $1.02 million due to lower activities under the Gates Foundation and CEPI grants and lower overall R&D activity;
  • Research and development expense declined 25% to $430,000 from $572,000 due to a decrease in third-party contract research services, partially offset by a rise in personnel costs and facilities and other costs;
  • General and administrative expenses were $1.45 million vs $1.48 million, falling 2%. Lower legal and professional services expenses were partially offset by higher business development services and other expenses;
  • Foreign currency exchange loss was $6,000 versus $13,000 due to fluctuations in the Euro-Dollar exchange rate;
  • Total other income was $455,000 vs a loss of $51,000 due to a gain in fair value of the warrant liability partially offset by warrant issuance costs and lower interest income;
  • Net loss amounted to $1.36 million vs $1.98 million. On a per share basis, net loss was $0.04 vs $0.06.

As of September 30th, 2026, cash, equivalents and short-term securities totaled $6.0 million compared to $8.6 million at the end of 2025. This includes restricted cash of about $1.5 million that is earmarked for work associated with the Gates Foundation Grant. Cash burn during the first nine months of 2026 was $5.3 million compared with $3.9 million for the same prior year period. During the third quarter, Dyadic reported $2.7 million of cash from financing predominantly related to the issuance of common stock and warrants. Due to the expiration of its shelf registration, Dyadic may not use its At-The-Market (ATM) sales agreement with Craig-Hallum until late December due to financing agreement restrictions. The company’s 10-Q filing notes that there is substantial doubt about Dyadic’s ability to continue as a going concern.

Strategic Collaboration with BRIG Bio and Strive Nutrition

On November 10th, Dyadic announced a strategic collaboration with existing partner BRIG BIO and new partner Strive Nutrition. Dyadic will contribute its Dapibus protein production platform and expertise in strain optimization and scale up with BRIG BIO’s precision-fermentation commercialization and regulatory capabilities. Strive will evaluate the Dapibus platform for the production of animal-free milk products along with other nutrition products. First, the collaborators will address development, scale-up and regulatory milestones along with quality qualification and signing of definitive commercial agreements. Initial commercial availability is expected to be greater than 10 metric tonnes after completing the Generally Recognized as Safe (GRAS) qualification process expected in 2028. Longer term, production could be more than 200 metric tonnes annually.

Strive Nutrition Corporation is a Wichita, Kansas-based company behind FREEMILK. It is a family-founded beverage business that sells animal-free milk alternatives containing real dairy protein produced through fermentation. Unlike soy, oat or almond milk, it is a dairy product, meaning it still carries milk allergens and is unsafe for people with true milk allergies. Strive was founded in 2017 by the Cohlmia family. Chairman and CEO Dennis Cohlmia previously led KanPak, an aseptic food and beverage packaging company. The company is privately held. The underlying technology is precision fermentation where microorganisms receive genetic instructions to produce a particular milk protein, which is then recovered and incorporated into food. Strive launched its beverages using Perfect Day’s animal-free whey. Its role is principally developing and commercializing finished nutrition products using proteins supplied by biotechnology partners.

Research License and Collaborative Development Agreement with Nutropy SAS

On July 17th, 2026, Dyadic signed a Research License and Collaborative Development Agreement with Nutropy SAS. Dyadic granted Nutropy an exclusive research license and a non-exclusive commercial license to use Dyadic’s Dapibus platform to develop casein proteins. Nutropy paid a $50,000 research license fee to Dyadic in the first year and may also pay milestones upon first regulatory approval and first commercial sales. Other contributions from the arrangement may include royalties based on gross margin, a share of sublicense revenue and an exclusivity fee if Nutropy elects this option.

Nutropy SAS is a French biotechnology startup developing milk proteins without cows. Its main focus is supplying dairy manufacturers with ingredients for cheese that can reproduce conventional cheese’s taste, texture, melt and stretch. It is primarily a business-to-business ingredient developer, rather than a consumer cheese brand. It was founded in 2021 by Nathalie Rolland and Dr. Maya Bendifallah, who serve as CEO and CSO respectively. Nutropy uses precision fermentation to engineer protein-producing expression systems that are compositionally equivalent to proteins in cow’s milk.

This agreement builds on a long line of cheese and dairy protein relationships by Dyadic extending to Leprino Foods in 2022 and advancing to Inzymes, BRIG BIO and Strive Nutrition among others.

C1 Produced Antibodies Advance Into Animal Studies

Dyadic’s November 12th press release updates investors on the Gates Foundation project that is evaluating C1 produced monoclonal antibodies (mAbs). The effort compares C1 produced mAbs for respiratory syncytial virus (RSV) and malaria against Chinese Hamster Ovary (CHO) cell versions of the mAb. The work recently advanced into animal studies which were initiated on October 20th, 2026. The study is designed to evaluate four groups of mice. The mice will receive C1 produced RSV and malaria antibodies and will be compared against mice receiving CHO produced counterparts.

The studies follow independent laboratory evaluations of antibodies produced using Dyadic’s C1 platform. Duke University conducted binding studies of both C1-produced RSM01 (RSV) and MAM01 (malaria), while IQVIA conducted neutralization testing of C1 produced RSM01. The animal studies will evaluate the pharmacokinetics of C1-produced RSV and malaria antibodies through direct comparisons with their respective CHO-produced counterparts and seek to generate additional preclinical data to support their continued advancement toward potential clinical development. C1 was able to achieve production yields of ~12.1 g/L for RSV antibody RSM01 and ~13.2 g/L for malaria antibody MAM01 in seven-day fermentation runs.

Results from the animal studies are expected to be reported in the first quarter 2027.

Inzymes

On March 2nd, 2026, Dyadic announced the planned commercialization of chymosin with its partner Inzymes. Chymosin is an enzyme that is used in the clotting of milk. The company will partner with Inzymes to commercialize the non-animal protein, building on the original September 2023 agreement. The arrangement follows the award of a $200,000 contractual milestone payment to Dyadic in March 2026. The partners cite a global market for dairy processing of $1.5 to $2.0 billion. Drivers for further growth include increasing cheese consumption and increasing demand for sustainable, fermentation-derived alternatives to animal-sourced enzymes.[1]

In November 2026, Inzymes reported its first commercial sale of the company’s second chymosin product: camel chymosin.[2] This product is manufactured using the Dapibus production strain. The commercial sale satisfies the first-commercial-sale milestone under the Inzymes agreement which qualifies Dyadic for a $225,000 milestone payment. It will be recognized as revenue in the fourth quarter of 2026.

Milestones and Events

  • Dyadic & Proliant commercial launch of recombinant human albumin – February 2026
  • Inzymes’ dairy enzyme (chymosin) milestone completion & planned future commercialization – March 2026
  • Dyadic & Fermbox launch recombinant DNase I (RNase free) – March 2026
  • Commercial partnership with IBT Bioservices announced – March 2026
  • Participation in the Lytham Partners Spring Investors Conference – May 2026
  • Scripps Research collaboration on rapid response hantavirus antibody & vaccine development – May 2026
  • Japan allowed Thermothelomyces heterothallica protein expression technology patent claims – June 2026
  • New industrial enzyme for advanced cellulose processing for paper & pulp industry – July 2026
  • Delivery of C1-produced antigens to FBS & Scripps Research for evaluation – July 2026
  • Nutropy agreement for additional precision-fermented dairy proteins – July 2026
  • NASDAQ non-compliance notice for minimum bid and market price – September 2026
  • Gates Foundation programs advance to animal studies – October 2026
  • Gates Foundation animal study results – 1Q:27
  • Completion of GRAS process for bovine α-lactalbumin (BRIG/Strive) – 2028

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

________________________

[1] Chymosin (also known as rennin) is a proteolytic enzyme (a type of protease) that plays a key role in cheese production by coagulating (curdling) milk. It is naturally produced in the stomach of newborn ruminant animals like calves and curdles the mother’s milk to slow digestion. In cheese manufacturing, chymosin causes milk to separate into solid curds and liquid whey. Most chymosin is now produced using recombinant methods that rely on precision fermentation.

[2] Camel chymosin is a milk-clotting enzyme naturally produced in the stomach of young camels. It helps them digest milk, and cheesemakers use it to turn liquid milk into curds, the starting material for cheese. It is the camel version of chymosin, an enzyme also found in calves.



Source link

- Advertisement -
- Advertisement -
- Advertisement -